VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in Melanoma

Cancer Immunology Research

Volumn 4, Issue 10, 2016, Pages 858-868

  Wu, Xinqi ^a   Giobbie Hurder, Anita ^b   Liao, Xiaoyun ^b,c   Lawrence, Donald ^d   McDermott, David ^e   Zhou, Jun ^a   Rodig, Scott ^b,c   Hodi, F Stephen ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; BEVACIZUMAB; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 3; CXCL1 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIAL CELL GROWTH FACTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; IPILIMUMAB; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CHEMOKINE; CXCL10 PROTEIN, HUMAN; CYTOKINE; ICAM1 PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; TNF PROTEIN, HUMAN; VASCULOTROPIN RECEPTOR;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CANCER PATIENT; CELL ADHESION; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; ENDOTHELIUM CELL; HUMAN; HUMORAL IMMUNITY; IN VITRO STUDY; LYMPHOCYTE MIGRATION; LYMPHOCYTIC INFILTRATION; MELANOMA CELL; MESENCHYMAL STEM CELL; METASTATIC MELANOMA; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; UPREGULATION; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; MALE; MELANOMA; METABOLISM; MIDDLE AGED; SECONDARY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CELL ADHESION; CHEMOKINE CXCL10; CHEMOKINES; CTLA-4 ANTIGEN; CYTOKINES; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; IPILIMUMAB; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84994097105     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0084     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-74.
2. Cipponi A, Wieers G, van Baren N, Coulie PG. Tumor-infiltrating lymphocytes: Apparently good for melanoma patients. But why? Cancer Immunol Immunother 2011; 60: 1153-60.
3. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: A meta-analysis. Breast Cancer Res Treat 2014; 148: 467-76.
4. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
5. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72: 1070-80.
6. Santoiemma PP, Powell DJ Jr Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther 2015; 16: 807-20.
7. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103.
8. Peske JD, Woods AB, Engelhard VH. Control of CD8 T-Cell infiltration into tumors by vasculature and microenvironment. Adv Cancer Res 2015; 128: 263-307.
9. Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res 2014; 74: 7168-74.
10. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: The role of angiogenic factors. Cancer Res 1996; 56: 1111-17.
11. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J Exp Med 1995; 181: 811-6.
12. Madhavan M, Srinivas P, Abraham E, Ahmed I, Vijayalekshmi NR, Balaram P. Down regulation of endothelial adhesion molecules in node positive breast cancer: Possible failure of host defence mechanism. Pathol Oncol Res 2002; 8: 125-8.
13. Dirkx AE, Oude Egbrink MG, Kuijpers MJ, van der Niet ST, Heijnen VV, Boumater Steege JC, et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322-9.
14. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E, Gillitzer R. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 1999; 189: 552-8.
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumabinpatients withmetastaticmelanoma. N Engl J Med 2010; 363: 711-23.
16. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
17. Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2: 632-42.
18. Wu X, Marmarelis ME, Hodi FS. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One 2013; 8: e56134.
19. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc 2007; 2: 805-10.
20. Groom JR, Luster AD. CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89: 207-15.
21. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69: 3077-85.
22. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: The leukocyte adhesioncascade updated. Nat Rev Immunol 2007; 7: 678-89.
23. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-71.
24. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487-501.
25. Sethi G, Sung B, Aggarwal BB. TNF: A master switch for inflammation to cancer. Front Biosci 2008; 13: 5094-107.
26. Mantovani A, Sica A. Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-7.
27. Voronov E, Carmi Y, Apte RN. The role IL-1 in tumor-mediated angiogenesis. Front Physiol 2014; 5: 114.
28. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115: 3632-9.
29. True AL, Rahman A, Malik AB. Activation of NF-kappaB induced by H(2)O (2) and TNF-alpha and its effects on ICAM1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 2000; 279: L302-11.
30. Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995; 270: 933-43.
31. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF, Dieterich LC, et al. VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB J 2015; 29: 227-38.
32. Griffioen AW, Damen CA, Blijham GH, Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996; 88: 667-73.
33. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20: 621-30.
34. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-80.
35. Yuan J, Zhou J, Dong Z, Tandon S, Kuk D, Panageas KS, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014; 2: 127-32.
36. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165: 35-44.
37. Singh UP, Singh S, Iqbal N, Weaver CT, McGhee JR, Lillard JW Jr IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res 2003; 23: 591-600.
38. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (CXCL10): A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997; 8: 207-19.
39. Lazzeri E, Romagnani P. CXCR3-binding chemokines: Novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 109-18.
40. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: Correlation with clinicopathological prognostic factors. J Clin Pathol 2007; 60: 596-9.
41. Jiang Z, Xu Y, Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep 2010; 37: 3029-36.
42. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010; 138: 1429-40.
43. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipi-limumab. Cancer Immunol Immunother 2012; 61: 1019-31.
44. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004; 64: 7697-701.
45. Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, et al. Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol 2012; 40: 560-6.
46. Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosup-pression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18: 5329-40.
47. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5: 200ra116.
48. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host typeIIFN signals arerequiredforantitumorCD8+Tcellresponsesthrough CD8{alpha}+ dendritic cells. J Exp Med 2011; 208: 2005-16.
49. Rafique I, Kirkwood JM, Tarhini AA. Immune checkpoint blockade and interferon-alpha in melanoma. Semin Oncol 2015; 42: 436-47.
50. Kudo-Saito C. Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol 2015; 3: 23.